Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)

NCT01972724 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01972724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01972724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
December 16, 2013
Completion date
October 17, 2016
Enrollment
114 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

type ii diabetes mellitus